Biosimilars are not a problem when it comes to the 12 year exclusivity. The exclusivity is based on the active moiety of the drug a biosimilar would infringe on that. Not having to do phase 3 and phase 4 trials is aimed at generics and biosimilars after the 12 year exclusivity is done.